CSS
LFCR icon

Cubist Systematic Strategies’s Lifecore Biomedical LFCR Stock Holding History

Cubist Systematic Strategies’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-10,538
Closed -$102K – 3676
2023
Q2 		$102K Buy
+10,538
New +$64.4K ﹤0.01% 2991
2023
Q1 		– Sell
-5,613
Closed -$36.4K – 4197
2022
Q4 		$36.4K Buy
5,613
+5,277
+1,571% +$43.5K ﹤0.01% 3940
2022
Q3 		$3K Buy
336
+310
+1,192% +$3.15K ﹤0.01% 4337
2022
Q2 		$0 Sell
26
-9,297
-100% -$92.1K ﹤0.01% 4453
2022
Q1 		$108K Buy
+9,323
New +$104K ﹤0.01% 3218
2021
Q3 		– Sell
-11,580
Closed -$130K – 3069
2021
Q2 		$130K Buy
+11,580
New +$133K ﹤0.01% 2681

Other funds holding LFCR

WC
Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return
LPAM
Legion Partners Asset Management Los Angeles, California $138M AUM 53.69% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CSC
Cove Street Capital El Segundo, California $76.6M AUM 36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VWA
Visionary Wealth Advisors O'fallon, Illinois $2.26B AUM 19.48% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return

Cubist Systematic Strategies's LFCR Position: Q3 2023 in Review

Cubist Systematic Strategies sold out of Lifecore Biomedical (LFCR) in Q3 2023, closing a stake of 10,538 shares — an estimated $102K sold.

Cubist Systematic Strategies first reported a position in LFCR in Q2 2021 and held it in 6 quarters. The position peaked at $130K in Q2 2021. 69 funds tracked by Wall St. Rank hold LFCR as of Q3 2023.

  • Cubist Systematic Strategies reported no remaining Lifecore Biomedical position as of Q3 2023 after selling out during the quarter.
  • Cubist Systematic Strategies sold 10,538 Lifecore Biomedical shares in Q3 2023, an estimated $102K.
  • Cubist Systematic Strategies first reported a position in Lifecore Biomedical in Q2 2021 and held it in 6 quarters.
  • Cubist Systematic Strategies's Lifecore Biomedical position peaked at $130K in Q2 2021.
  • 69 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q3 2023.

Based on Cubist Systematic Strategies's 13F filing for Q3 2023, filed 14 Nov 2023.